INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IUI1 - US46120E6023 - Common Stock
487.95 EUR
-11.6 (-2.32%)
Overall IUI1 gets a fundamental rating of 6 out of 10. We evaluated IUI1 against 68 industry peers in the Health Care Equipment & Supplies industry. IUI1 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IUI1 shows excellent growth, but is valued quite expensive already. With these ratings, IUI1 could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year IUI1 was profitable.
IUI1 had a positive operating cash flow in the past year.
Each year in the past 5 years IUI1 has been profitable.
Each year in the past 5 years IUI1 had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 14.19%, IUI1 belongs to the best of the industry, outperforming 92.65% of the companies in the same industry.
IUI1's Return On Equity of 16.12% is amongst the best of the industry. IUI1 outperforms 83.82% of its industry peers.
IUI1's Return On Invested Capital of 11.69% is amongst the best of the industry. IUI1 outperforms 82.35% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IUI1 is in line with the industry average of 9.73%.
The 3 year average ROIC (9.53%) for IUI1 is below the current ROIC(11.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROIC | 11.69% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
IUI1 has a better Profit Margin (28.58%) than 97.06% of its industry peers.
IUI1's Profit Margin has declined in the last couple of years.
IUI1 has a Operating Margin of 29.44%. This is amongst the best in the industry. IUI1 outperforms 98.53% of its industry peers.
In the last couple of years the Operating Margin of IUI1 has declined.
The Gross Margin of IUI1 (66.38%) is better than 75.00% of its industry peers.
IUI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
The number of shares outstanding for IUI1 has been increased compared to 1 year ago.
Compared to 5 years ago, IUI1 has more shares outstanding
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.18
WACC9.94%
2.3 Liquidity
A Current Ratio of 4.97 indicates that IUI1 has no problem at all paying its short term obligations.
The Current ratio of IUI1 (4.97) is better than 95.59% of its industry peers.
A Quick Ratio of 4.20 indicates that IUI1 has no problem at all paying its short term obligations.
IUI1 has a better Quick ratio (4.20) than 95.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 |
3. Growth
3.1 Past
IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.12%, which is quite impressive.
Measured over the past years, IUI1 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 11.48% on average per year.
IUI1 shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.18%.
The Revenue has been growing by 13.27% on average over the past years. This is quite good.
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
3.2 Future
IUI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.67% yearly.
IUI1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.12% yearly.
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.67%
Revenue Next Year21.32%
Revenue Next 2Y18.09%
Revenue Next 3Y16.5%
Revenue Next 5Y14.12%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 65.94 indicates a quite expensive valuation of IUI1.
Compared to the rest of the industry, the Price/Earnings ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 60.29% of the companies listed in the same industry.
IUI1's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.25.
IUI1 is valuated quite expensively with a Price/Forward Earnings ratio of 57.25.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 72.06% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of IUI1 to the average of the S&P500 Index (23.98), we can say IUI1 is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.94 | ||
| Fwd PE | 57.25 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than the industry average as 67.65% of the companies are valued more cheaply.
IUI1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 88.66 | ||
| EV/EBITDA | 57.33 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
IUI1 has an outstanding profitability rating, which may justify a higher PE ratio.
IUI1's earnings are expected to grow with 15.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.28
PEG (5Y)5.74
EPS Next 2Y16.35%
EPS Next 3Y15.9%
5. Dividend
5.1 Amount
No dividends for IUI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IUI1 (1/12/2026, 7:00:00 PM)
487.95
-11.6 (-2.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners88.29%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap172.98B
Revenue(TTM)9.61B
Net Income(TTM)2.75B
Analysts77
Price Target523.6 (7.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)11.61%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)13.53%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)11%
EPS beat(12)11
Avg EPS beat(12)7.6%
EPS beat(16)13
Avg EPS beat(16)5.75%
Revenue beat(2)2
Avg Revenue beat(2)2%
Min Revenue beat(2)1.84%
Max Revenue beat(2)2.17%
Revenue beat(4)4
Avg Revenue beat(4)2.55%
Min Revenue beat(4)1.09%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)6
Avg Revenue beat(12)0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.31%
PT rev (1m)-0.15%
PT rev (3m)2.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.15%
EPS NY rev (1m)0%
EPS NY rev (3m)5.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.65%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)1.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.94 | ||
| Fwd PE | 57.25 | ||
| P/S | 20.95 | ||
| P/FCF | 88.66 | ||
| P/OCF | 68.02 | ||
| P/B | 11.82 | ||
| P/tB | 12.06 | ||
| EV/EBITDA | 57.33 |
EPS(TTM)7.4
EY1.52%
EPS(NY)8.52
Fwd EY1.75%
FCF(TTM)5.5
FCFY1.13%
OCF(TTM)7.17
OCFY1.47%
SpS23.29
BVpS41.29
TBVpS40.45
PEG (NY)3.28
PEG (5Y)5.74
Graham Number82.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROCE | 16.61% | ||
| ROIC | 11.69% | ||
| ROICexc | 23.14% | ||
| ROICexgc | 24.12% | ||
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% | ||
| FCFM | 23.63% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexgc growth 3Y-7.59%
ROICexgc growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.36% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.84% | ||
| Profit Quality | 82.69% | ||
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 | ||
| Altman-Z | N/A |
F-Score8
WACC9.94%
ROIC/WACC1.18
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.67%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
Revenue Next Year21.32%
Revenue Next 2Y18.09%
Revenue Next 3Y16.5%
Revenue Next 5Y14.12%
EBIT growth 1Y36.82%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year45.96%
EBIT Next 3Y24.75%
EBIT Next 5Y20.85%
FCF growth 1Y80.69%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y46.32%
OCF growth 3Y4.95%
OCF growth 5Y8.61%
INTUITIVE SURGICAL INC / IUI1.DE FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.
Can you provide the valuation status for INTUITIVE SURGICAL INC?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 8 / 10.
Can you provide the financial health for IUI1 stock?
The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 7 / 10.